DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell Disease
MaxCyte, a US-based global company dedicated to driving the acceleration of discovery, development, manufacturing and commercialization of next-generation, cell-based medicines, announced today it will present positive preclinical study results at the American Society of Gene and Cell Therapy Annual Meeting (ASGCT). The new in vitro data demonstrate the potential of MaxCyte’s cGMP-compliant proprietary delivery platform to enable CRISPR gene editing in the treatment of sickle cell disease (SCD). The ASGCT meeting will take place in Washington, DC from May 10-13, 2017.


Related Content
-
news & eventsA new Sickle Cell Disease Drug Holds Much Promise but Most Sufferers Won’t be Able to Afford itThe regulatory approval of a groundbreak...
-
education & researchHydroxyurea to Lower Transcranial Doppler Velocities and Prevent Primary Stroke: The Uganda NOHARM Sickle Cell Anemi...In sub-Saharan Africa, sickle cell anemi...
-
news & eventsHHS Secretary Alex Azar Touts White House Efforts to Fight Sickle Cell DiseaseBy 2029, Americans with sickle cell dise...
-
news & eventsMarijuana use common in sickle cell patients, highlighting need for more research, study showsMany sickle cell disease (SCD)...
-
education & researchTreatment options for sickle cell disease – chronic blood transfusionsBlood transfusions are scheduled and giv...
-
news & eventsFDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell DiseaseToday, the U.S. Food and Drug Administra...
-
news & eventsMaxCyte and U.S. National Institutes of Health’s National Heart, Lung, and Blood Institute enter cooperative r...MaxCyte, Inc. today announces it has e...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.